$ACET News

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months

Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis - Slideshow

Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28

Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance

Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript

Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34

Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Adicet Bio To Report Clinical Data From Phase 1 Study Evaluating Prulacabtagene Leucel As Potential Treatment For Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis On September 28

HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $27 Price Target

Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?

Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Adicet Bio Reveals FDA Clearance Of IND Application For ADI-212; Co Plans To Initiate Phase 1 Enrollment In Patients With mCRPC In Q4 Of 2026

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet